Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.
about
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveVoriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.Voriconazole in the management of nosocomial invasive fungal infections.Supportive care in patients with acute leukaemia: historical perspectives.Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital.Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.Prophylactic antifungal agents used after lung transplantation.Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective reviewTreatment principles for the management of mold infections.Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: "real life" evaluation.Granulocyte transfusion therapy: randomization after all?Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis.Invasive aspergillosis and allogeneic hematopoietic stem cell transplantation in children: a 15-year experience.Invasive coinfection with Aspergillus and Mucor in a patient with acute myeloid leukemia.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
P2860
Q28388806-E09139E2-A9EA-4514-BDE4-0D05C212964FQ34166590-15D27733-2E1D-46F5-BAC2-EB21C76BD427Q34532546-CC728485-9168-4AE5-86AA-0E4E230C759DQ34756973-1053E517-5A4E-4713-9A34-2D8A50FBA7F1Q35166823-E2B459A7-FED3-4B17-996A-F83E6D88E8BDQ35265135-DF15E608-4753-4E5D-92CB-D2944CA18BADQ35687657-D8263DDC-F719-491A-B95D-EBC3F347D338Q35821259-8FE1FCD8-A00A-4DCD-B507-43DE09269A85Q36046991-F21AE641-39CF-49CC-B8F3-4CFAF0191FD1Q36505508-C392CE19-35E5-41D2-A389-92D1BAA31E6FQ36867435-9FDAD2C7-B4DD-44B2-86E2-B7B726304D20Q37150434-BEC0292E-93C8-4EA9-B1FC-3EE64E61A1B8Q37442798-CD9CEEA3-5924-4A8F-B676-E80A1BB49F14Q37697380-895F663E-9736-4FB2-BB30-6E85A9259FF2Q37935599-117EFF2A-5B6D-4856-A144-0E3E4E47EEABQ37993110-D9DA8CD6-F172-4215-9E28-1A1EA478B276Q38111391-75B3BB47-6FEA-4A7F-B925-8EEA6B9245D0Q38265845-6DC39A0D-129E-4EF1-887E-DF72DE9E06A3Q40360694-D3278A07-C1D6-4CC3-B6A5-CF930EB4884AQ40886644-7B5087F0-F19C-4E7F-B1A4-1358FD781734Q42956275-7DC2F748-15C5-4B65-84C4-BF926A1082C0Q42970799-4E5480B8-A104-4185-B5B6-3CC8FE2B5F20Q44558731-B868DCF1-A704-4252-8C4B-BC9B630C8D2CQ45757964-197149EC-3FC4-458E-AD0B-42E51CD464F6Q46709631-B2F687E0-DB66-4458-9AAF-3D357F5329D5Q51169948-1CA2628A-7313-4E20-A313-A38AA8A88890Q51617424-3251AC17-A09B-4575-BD93-F4DDDC9D5205
P2860
Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Secondary antifungal prophylax ...... em cell transplant recipients.
@en
Secondary antifungal prophylax ...... em cell transplant recipients.
@nl
type
label
Secondary antifungal prophylax ...... em cell transplant recipients.
@en
Secondary antifungal prophylax ...... em cell transplant recipients.
@nl
prefLabel
Secondary antifungal prophylax ...... em cell transplant recipients.
@en
Secondary antifungal prophylax ...... em cell transplant recipients.
@nl
P2093
P2860
P356
P1476
Secondary antifungal prophylax ...... em cell transplant recipients.
@en
P2093
Castaigne S
Cordonnier C
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704469
P407
P577
2004-05-01T00:00:00Z
P5875
P6179
1002235220